Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 07 2023
0mins
Source: globenewswire
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELOX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELOX
Wall Street analysts forecast ELOX stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 11.000
Low
Averages
High
Current: 11.000
Low
Averages
High
No data
About ELOX
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Companies See Significant Stock Gains
- Regentis Stock Surge: Regentis Biomaterials Ltd. shares soared over 88% as the company prepares to commence European Surgeon Training for GelrinC in Q3 2026, accelerating its commercialization efforts in knee cartilage repair and enhancing its competitive edge in the market.
- Eloxx Uplisting Success: Eloxx Pharmaceuticals Inc. saw its stock rise more than 77% after uplisting to Nasdaq, with plans to issue 2.975 million shares at $11.00 each, expected to generate $66 million in revenue, supporting its clinical trials for Alport syndrome treatment.
- Alignment Healthcare Gains: Alignment Healthcare Inc. shares increased over 25% following disclosures of RSU grants to executives, with projected Q2 2026 revenues between $1.295 billion and $1.315 billion, indicating strong growth potential in the healthcare sector.
- Cartesian Strategic Licensing: Cartesian Therapeutics Inc. inked a strategic licensing deal with WestGene Biopharma to advance CAR-T therapies for autoimmune diseases, with a Phase 1 trial expected to start in 2H 2026, potentially driving innovation in this therapeutic area.
See More
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
See More
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
See More
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
See More
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
See More
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
See More
Biotech Companies See Significant Stock Gains
- Regentis Stock Surge: Regentis Biomaterials Ltd. shares soared over 88% as the company prepares to commence European Surgeon Training for GelrinC in Q3 2026, accelerating its commercialization efforts in knee cartilage repair and enhancing its competitive edge in the market.
- Eloxx Uplisting Success: Eloxx Pharmaceuticals Inc. saw its stock rise more than 77% after uplisting to Nasdaq, with plans to issue 2.975 million shares at $11.00 each, expected to generate $66 million in revenue, supporting its clinical trials for Alport syndrome treatment.
- Alignment Healthcare Gains: Alignment Healthcare Inc. shares increased over 25% following disclosures of RSU grants to executives, with projected Q2 2026 revenues between $1.295 billion and $1.315 billion, indicating strong growth potential in the healthcare sector.
- Cartesian Strategic Licensing: Cartesian Therapeutics Inc. inked a strategic licensing deal with WestGene Biopharma to advance CAR-T therapies for autoimmune diseases, with a Phase 1 trial expected to start in 2H 2026, potentially driving innovation in this therapeutic area.
See More
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
See More
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
See More
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
See More
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
See More
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013
See More
